Unique Biomarkers Identified for Use in Thyroid Cancer Follow-Up January 2017 | Researchers have identified two unique biomarkers that show promise for monitoring patients who have received treatment for papillary thyroid cancer (PTC), according to a study recently published in the new open access Journal of the Endocrine Society…
Explore highlights of current education across the Endocrine Society.
Selecting a Target in Refractory Cushing Disease
ENDO Session | No credit available
Maria Fleseriu, MD
What’s your best option? Use the latest information on medical therapies from clinical trials to treat your patients with persistent disease.
Evaluation and Management of Neuroendocrine Tumors
ENDO Session | No credit available
Faculty: Karel Pacak, MD; Wouter W. de Herder, MD; and Thomas M. O’Dorisio
Hear cases, learn strategies, and test yourself on the diagnosis, localization, and treatment of NETs.
Hormones and Cancer Digital Toolkit Patient Resource | No credit available
Reviewer: Richard J. Santen, MD
Interactive and downloadable resources and information for patients with questions about endocrine-related cancers.
Cancer Risks in Patients Treated with Growth Hormone in Childhood: The SAGhE European Cohort Study JCEM | February 10, 2017 Anthony J Swerdlow, Rosie Cooke, Dominique Beckers, Birgit Borgström, Gary Butler, Jean-Claude Carel, Stefano Cianfarani, Peter Clayton, Joël Coste, Annalisa Deodati, Emmanuel Ecosse, Ruth Gausche, Claudio Giacomozzi, Anita CS. Hokken-Koelega, Aysha J Khan, Wieland Kiess, Claudia E. Kuehni, Primus-E. Mullis, Roland Pfaffle, Lars Sävendahl, Grit Sommer, Muriel Thomas, Anders Tidblad, Sally Tollerfield, Liesbet Van Eycken, and Gladys RJ. Zandwijken
Context: Growth Hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited…
Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib JCEM | October 18, 2016 Weibin Wang, Helen Kang, Yinu Zhao, Irene Min, Brian Wyrwas, Maureen Moore, Lisong Teng, Rasa Zarnegar, Xuejun Jiang, and Thomas J. Fahey, III
Thyroid cancer incidence has increased significantly in recent years, and it is currently the fifth most frequently diagnosed…
Long-Term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study JCEM | October 12, 2016 Yul Hwangbo, Jung Min Kim, Young Joo Park, Eun Kyung Lee, You Jin Lee, Do Joon Park, Young Sik Choi, Kang Dae Lee, Seo Young Sohn, Sun Wook Kim, Jae Hoon Chung, Dong Jun Lim, Min Hee Kim, Min Joo Kim, Young Suk Jo, Min Ho Shong, Sung-Soo Koong, Jong Ryeal Hahm, Jung Hwa Jung, and Ka Hee Yi
Thyroid cancer is the most common malignancy in Korea. According to the statistics of the Korea Central Cancer Registry…
Clinical, Sonographic, and Pathological Characteristics of RAS-Positive versus BRAF-Positive Thyroid Carcinoma JCEM | September 30, 2016 Sujay Kakarmath, Howard T. Heller, Caroline A. Alexander, Edmund S. Cibas, Jeffrey F. Krane, Justine A. Barletta, Neal I. Lindeman, Mary C. Frates, Carol B. Benson, Atul A. Gawande, Nancy L. Cho, Matthew Nehs, Francis D. Moore, Ellen Marqusee, Mathew I. Kim, P. Reed Larsen, Norra Kwong, Trevor E. Angell, and Erik K. Alexander
Mutations in the BRAF and RAS oncogenes are responsible for most well-differentiated thyroid cancer. Yet, our clinical understanding of how BRAF-positive and RAS-positive thyroid cancers…
Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin JCEM | September 7, 2016 Rachel J. Watkins, Waraporn Imruetaicharoenchoke, Martin L. Read, Neil Sharma, Vikki L. Poole, Erica Gentilin, Sukhchain Bansal, Emy Bosseboeuf, Rachel Fletcher, Hannah R. Nieto, Ujjal Mallick, Allan Hackshaw, Hisham Mehanna, Kristien Boelaert, Vicki E. Smith, and Christopher J. McCabe
Context: Metastatic disease is responsible for the majority of endocrine cancer deaths. New therapeutic targets are urgently needed to improve patient survival rates. Objective…
A Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1 JCEM | June 2, 2016 Øyvind Bruserud, Bergithe E. Oftedal, Nils Landegren, Martina M. Erichsen, Eirik Bratland, Kari Lima, Anders P. Jørgensen, Anne G. Myhre, Johan Svartberg, Kristian J. Fougner, Åsne Bakke, Bjørn G. Nedrebø, Bjarne Mella, Lars Breivik, Marte K. Viken, Per M. Knappskog, Mihaela C. Marthinussen, Kristian Løvås, Olle Kämpe, Anette B. Wolff, and Eystein S. Husebye
Context: Autoimmune polyendocrine syndrome type 1 (APS1) is a childhood-onset monogenic disease defined by the presence of two of the three major components: hypoparathyroidism, primary…
Treatment of Cushing's Syndrome JCEM | July 29, 2015 Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, M. Hassan Murad, John Newell-Price, Martin O. Savage, and Antoine Tabarin
Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes…
Diagnosis and Treatment of Pheochromocytoma and Paraganglioma JCEM | June 03, 2014 Jacques W. M. Lenders, Quan-Yang Duh, Graeme Eisenhofer, Anne-Paule Gimenez-Roqueplo, Stefan K. G. Grebe, Mohammad Hassan Murad, Mitsuhide Naruse, Karel Pacak, and William F. Young Jr
The Task Force recommends that initial biochemical testing for PPGLs should include measurements of plasma free or urinary fractionated metanephrines. Consideration should be given to preanalytical factors…
The Diagnosis of Cushing's Syndrome JCEM | January 14, 2009 Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, John Newell-Price, Martin O. Savage, Paul M. Stewart, and Victor M. Montori
After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with…
For additional meetings, visit the Endocrine Society’s Worldwide Endocrinology Calendar at endocrine.org/calendar.
Clinical Endocrinology Update & Endocrine Board Review Dates: September 23–27, 2017 Location: Chicago, Illinois, United States Sponsor: Endocrine Society
Whether you need the latest clinical information or you’re preparing to certify or recertify for the boards, Clinical Endocrinology Update (CEU) and Endocrine Board Review (EBR) have you covered.
ENDO Bridge Dates: October 19–22, 2017 Location: Antalya, Turkey Sponsor: Endocrine Society, the European Society of Endocrinology, and The Society of Endocrinology and Metabolism of Turkey
EndoBridge will provide a comprehensive update in the field of endocrinology for the clinical endocrinologist. The official language of the meeting is English, but simultaneous translation will be available in Russian, Arabic, and Turkish
ENDO 2018 Dates: March 17–20, 2018 Location: Chicago, Illinois, United States Sponsor: Endocrine Society
ENDO is the world’s largest event for presenting and obtaining the latest in endocrine science and medicine with an extensive program covering a broad array of topics, various networking opportunities, poster sessions, updates on new products and technologies at the ENDOExpo, and more.